Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?
Jiménez-Ubieto A, Paiva B, Puig N, Cedena MT, Martínez-López J, Oriol A, Blanchard MJ, Ríos R, Martin J, Martínez R, Sureda A, Hernández MT, de la Rubia J, Krnisk I, Cabañas V, Palomera L, Sánchez-Pina JM, Bargay J, Mateos MV, Rosiñol L, Blade J, San Miguel J, Lahuerta JJ; GEM (Grupo Español de Mieloma)/PETHEMA (Programa Español de Tratamientos en Hematología) Cooperative Study Group. Jiménez-Ubieto A, et al. Blood. 2021 Nov 11;138(19):1901-1905. doi: 10.1182/blood.2021012319. Blood. 2021. PMID: 34329372 Free PMC article. Clinical Trial. No abstract available.
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.
Hernández-Boluda JC, Pereira A, Pastor-Galán I, Alvarez-Larrán A, Savchuk A, Puerta JM, Sánchez-Pina JM, Collado R, Díaz-González A, Angona A, Sagüés M, García-Gutiérrez V, Boqué C, Osorio S, Vallansot R, Palomera L, Mendizábal A, Casado LF, Pérez-Encinas M, Pérez-López R, Ferrer-Marín F, Sánchez-Guijo F, García C, Heras NL, López-Lorenzo JL, Cervantes F, Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC). Hernández-Boluda JC, et al. Blood Cancer J. 2018 Dec 2;8(10):91. doi: 10.1038/s41408-018-0125-0. Blood Cancer J. 2018. PMID: 30504932 Free PMC article.
A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics.
Sánchez R, Ribera J, Morgades M, Ayala R, Onecha E, Ruiz-Heredia Y, Juárez-Rufián A, de Nicolás R, Sánchez-Pina J, Vives S, Zamora L, Mercadal S, Coll R, Cervera M, García O, Ribera JM, Martínez-López J. Sánchez R, et al. Blood Cancer J. 2020 Apr 24;10(4):43. doi: 10.1038/s41408-020-0308-3. Blood Cancer J. 2020. PMID: 32332702 Free PMC article.
The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements.
Cedena MT, Martin-Clavero E, Wong S, Shah N, Bahri N, Alonso R, Barcenas C, Valeri A, Salazar Tabares J, Sanchez-Pina J, Cuellar C, Martin T, Wolf J, Lahuerta JJ, Martinez-Lopez J. Cedena MT, et al. PLoS One. 2020 Aug 31;15(8):e0237155. doi: 10.1371/journal.pone.0237155. eCollection 2020. PLoS One. 2020. PMID: 32866200 Free PMC article.
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.
Leivas A, Valeri A, Córdoba L, García-Ortiz A, Ortiz A, Sánchez-Vega L, Graña-Castro O, Fernández L, Carreño-Tarragona G, Pérez M, Megías D, Paciello ML, Sánchez-Pina J, Pérez-Martínez A, Lee DA, Powell DJ Jr, Río P, Martínez-López J. Leivas A, et al. Blood Cancer J. 2021 Aug 14;11(8):146. doi: 10.1038/s41408-021-00537-w. Blood Cancer J. 2021. PMID: 34392311 Free PMC article.
Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
Martinez-Lopez J, Alonso R, Wong SW, Rios R, Shah N, Ruiz-Heredia Y, Sanchez-Pina JM, Sanchez R, Bahri N, Zamanillo I, Poza M, Buenache N, Encinas C, Juarez L, Miras F, Collado L, Barrio S, Martin T, Cedena MT, Wolf J. Martinez-Lopez J, et al. Among authors: sanchez pina jm. J Hematol Oncol. 2021 Aug 17;14(1):126. doi: 10.1186/s13045-021-01135-w. J Hematol Oncol. 2021. PMID: 34404440 Free PMC article.
Impact of COVID-19 in patients with multiple myeloma based on a global data network.
Martinez-Lopez J, Hernandez-Ibarburu G, Alonso R, Sanchez-Pina JM, Zamanillo I, Lopez-Muñoz N, Iñiguez R, Cuellar C, Calbacho M, Paciello ML, Ayala R, García-Barrio N, Perez-Rey D, Meloni L, Cruz J, Pedrera-Jiménez M, Serrano-Balazote P, de la Cruz J. Martinez-Lopez J, et al. Among authors: sanchez pina jm. Blood Cancer J. 2021 Dec 10;11(12):198. doi: 10.1038/s41408-021-00588-z. Blood Cancer J. 2021. PMID: 34893583 Free PMC article.
Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network.
Sanz A, Ayala R, Hernández G, Lopez N, Gil-Alos D, Gil R, Colmenares R, Carreño-Tarragona G, Sánchez-Pina J, Alonso RA, García-Barrio N, Pérez-Rey D, Meloni L, Calbacho M, Cruz-Rojo J, Pedrera-Jiménez M, Serrano-Balazote P, de la Cruz J, Martínez-López J. Sanz A, et al. Blood Cancer J. 2022 Jun 24;12(6):94. doi: 10.1038/s41408-022-00692-8. Blood Cancer J. 2022. PMID: 35750670 Free PMC article. No abstract available.
Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study.
Ayala R, Fernández RA, García-Gutiérrez V, Alvarez-Larrán A, Osorio S, Sánchez-Pina JM, Carreño-Tarragona G, Álvarez N, Gómez-Casares MT, Duran A, Gorrochategi J, Hernández-Boluda JC, Martínez-López J. Ayala R, et al. Among authors: sanchez pina jm. EJHaem. 2023 Apr 16;4(2):401-409. doi: 10.1002/jha2.685. eCollection 2023 May. EJHaem. 2023. PMID: 37206258 Free PMC article.
33 results